Advertisement
Advertisement

PRME

PRME logo

Prime Medicine, Inc. Common Stock

3.81
USD
Sponsored
-0.34
-8.14%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

3.84

+0.03
+0.73%

PRME Earnings Reports

Positive Surprise Ratio

PRME beat 3 of 12 last estimates.

25%

Next Report

Date of Next Report
Feb 27, 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.39M
/
-$0.25
Implied change from Q3 25 (Revenue/ EPS)
+94.89%
/
-21.88%
Implied change from Q4 24 (Revenue/ EPS)
+9.36%
/
-19.35%

Prime Medicine, Inc. Common Stock earnings per share and revenue

On Nov 07, 2025, PRME reported earnings of -0.32 USD per share (EPS) for Q3 25, missing the estimate of -0.25 USD, resulting in a -23.98% surprise. Revenue reached 1.23 million, compared to an expected 1.05 million, with a 17.04% difference. The market reacted with a -8.85% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of -0.25 USD, with revenue projected to reach 2.39 million USD, implying an decrease of -21.88% EPS, and increase of 94.89% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Prime Medicine, Inc. Common Stock reported EPS of -$0.32, missing estimates by -23.98%, and revenue of $1.23M, 17.04% above expectations.
The stock price moved down -8.85%, changed from $4.18 before the earnings release to $3.81 the day after.
The next earning report is scheduled for Feb 27, 2026.
Based on 14 analysts, Prime Medicine, Inc. Common Stock is expected to report EPS of -$0.25 and revenue of $2.39M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement